Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Invest Dermatol. 2016 Oct 7;137(2):506–512. doi: 10.1016/j.jid.2016.09.027

Figure 1. CCAR2 and SIRT1 proteins are stablized in squamous cell carcinoma.

Figure 1

(a) Histology (H&E) and Immunofluorescence of CCAR2 (green) and Keratin 14 (K14, red) protein expression in normal human skin and Squamous Cell Carcinoma (SCC) frozen sections. DAPI (blue) stains the nucleus. Scale = 50μm. (b) Western blot analysis of CCAR2 and SIRT1 protein in keratinocytes (OKF6, P1-Ep and N) and SCC (SCC-13, SCC-25, JHU-029 and HO1N1) cell lines. GAPDH provides the loading control. (c) Quantitative RT-PCR of CCAR2 (left) and SIRT1 (right) mRNA expression in keratinocytes (Ker) and SCC cell lines. p > 0.05, not significant (N.S.). (d) Western blot of CCAR2 and SIRT1 protein expression in keratinocytes (N, P1-Ep) and SCC (HO1N1 and JHU-029) cell lines treated with Cyclohexamide (CHX, 100 μg/ml) for 0, 2, 4, 6 or 8 hours. GAPDH provides the loading control.